104 related articles for article (PubMed ID: 23381743)
1. Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?
Narod SA; Metcalfe K; Lynch HT; Ghadirian P; Robidoux A; Tung N; Gaughan E; Kim-Sing C; Olopade OI; Foulkes WD; Robson M; Offit K; Jakubowska A; Byrski T; Huzarski T; Sun P; Lubinski J
Breast Cancer Res Treat; 2013 Feb; 138(1):273-9. PubMed ID: 23381743
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA
N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123
[TBL] [Abstract][Full Text] [Related]
3. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
4. Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer.
Huzarski T; Byrski T; Gronwald J; Górski B; Domagala P; Cybulski C; Oszurek O; Szwiec M; Gugala K; Stawicka M; Morawiec Z; Mierzwa T; Janiszewska H; Kilar E; Marczyk E; Kozak-Klonowska B; Siolek M; Surdyka D; Wisniowski R; Posmyk M; Sun P; Lubinski J; Narod SA
J Clin Oncol; 2013 Sep; 31(26):3191-6. PubMed ID: 23940229
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
[TBL] [Abstract][Full Text] [Related]
6. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.
Pierce LJ; Levin AM; Rebbeck TR; Ben-David MA; Friedman E; Solin LJ; Harris EE; Gaffney DK; Haffty BG; Dawson LA; Narod SA; Olivotto IA; Eisen A; Whelan TJ; Olopade OI; Isaacs C; Merajver SD; Wong JS; Garber JE; Weber BL
J Clin Oncol; 2006 Jun; 24(16):2437-43. PubMed ID: 16636335
[TBL] [Abstract][Full Text] [Related]
7. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Metcalfe K; Lynch HT; Ghadirian P; Tung N; Kim-Sing C; Olopade OI; Domchek S; Eisen A; Foulkes WD; Rosen B; Vesprini D; Sun P; Narod SA
Breast Cancer Res Treat; 2011 May; 127(1):287-96. PubMed ID: 21221768
[TBL] [Abstract][Full Text] [Related]
8. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
Goffin JR; Chappuis PO; Bégin LR; Wong N; Brunet JS; Hamel N; Paradis AJ; Boyd J; Foulkes WD
Cancer; 2003 Feb; 97(3):527-36. PubMed ID: 12548593
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
Kriege M; Seynaeve C; Meijers-Heijboer H; Collee JM; Menke-Pluymers MB; Bartels CC; Tilanus-Linthorst MM; Blom J; Huijskens E; Jager A; van den Ouweland A; van Geel B; Hooning MJ; Brekelmans CT; Klijn JG
J Clin Oncol; 2009 Aug; 27(23):3764-71. PubMed ID: 19564533
[TBL] [Abstract][Full Text] [Related]
10. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
[TBL] [Abstract][Full Text] [Related]
11. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Metcalfe K; Lynch HT; Ghadirian P; Tung N; Olivotto I; Warner E; Olopade OI; Eisen A; Weber B; McLennan J; Sun P; Foulkes WD; Narod SA
J Clin Oncol; 2004 Jun; 22(12):2328-35. PubMed ID: 15197194
[TBL] [Abstract][Full Text] [Related]
12. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.
Kaplan HG; Malmgren JA; Atwood M
Breast J; 2009; 15(5):454-60. PubMed ID: 19671105
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
14. Body weight correlates with mortality in early-stage breast cancer.
Enger SM; Greif JM; Polikoff J; Press M
Arch Surg; 2004 Sep; 139(9):954-58; discussion 958-60. PubMed ID: 15381612
[TBL] [Abstract][Full Text] [Related]
15. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer.
Foulkes WD; Wong N; Brunet JS; Bégin LR; Zhang JC; Martinez JJ; Rozen F; Tonin PN; Narod SA; Karp SE; Pollak MN
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2465-9. PubMed ID: 9815648
[TBL] [Abstract][Full Text] [Related]
16. Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program.
Møller P; Stormorken A; Jonsrud C; Holmen MM; Hagen AI; Clark N; Vabø A; Sun P; Narod SA; Mæhle L
Breast Cancer Res Treat; 2013 May; 139(1):155-61. PubMed ID: 23615785
[TBL] [Abstract][Full Text] [Related]
17. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
[TBL] [Abstract][Full Text] [Related]
18. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.
Kirova YM; Savignoni A; Sigal-Zafrani B; de La Rochefordiere A; Salmon RJ; This P; Asselain B; Stoppa-Lyonnet D; Fourquet A
Breast Cancer Res Treat; 2010 Feb; 120(1):119-26. PubMed ID: 20033769
[TBL] [Abstract][Full Text] [Related]
19. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
Vaziri SA; Krumroy LM; Elson P; Budd GT; Darlington G; Myles J; Tubbs RR; Casey G
Clin Cancer Res; 2001 Jul; 7(7):1937-45. PubMed ID: 11448907
[TBL] [Abstract][Full Text] [Related]
20. Use and outcomes of adjuvant chemotherapy in older women with breast cancer.
Giordano SH; Duan Z; Kuo YF; Hortobagyi GN; Goodwin JS
J Clin Oncol; 2006 Jun; 24(18):2750-6. PubMed ID: 16782915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
